Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRSP CRISPR Therapeutics	$53.05 -0.9%	$55.59	$30.04 ▼ $71.13	$4.87B	1.8	2.69 million shs	1.45 million shs
MRUS Merus	$66.10 -1.8%	$61.00	$33.19 ▼ $69.20	$5.09B	1.09	582,414 shs	1.10 million shs
NUVL Nuvalent	$76.02 -0.1%	$78.51	$55.53 ▼ $113.51	$5.49B	1.3	427,783 shs	511,984 shs
SNDX Syndax Pharmaceuticals	$16.32 +0.4%	$11.35	$8.58 ▼ $22.50	$1.40B	0.74	3.02 million shs	2.24 million shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRSP CRISPR Therapeutics	-2.46%	+0.87%	-16.03%	+45.54%	+10.97%
MRUS Merus	+0.63%	+4.42%	+2.58%	+21.51%	+26.92%
NUVL Nuvalent	+1.60%	+3.95%	-7.09%	+1.83%	-9.67%
SNDX Syndax Pharmaceuticals	+2.59%	+3.30%	+69.91%	+53.11%	-21.86%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRSP CRISPR Therapeutics	3.53 of 5 stars	4.3	3.0	0.0	1.7	3.3	0.6
MRUS Merus	2.3188 of 5 stars	3.5	1.0	0.0	3.5	2.5	0.0
NUVL Nuvalent	3.3772 of 5 stars	4.5	1.0	0.0	3.4	3.3	0.0
SNDX Syndax Pharmaceuticals	3.926 of 5 stars	4.5	0.0	4.4	2.5	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRSP CRISPR Therapeutics	2.47	Hold	$71.60	34.97% Upside
MRUS Merus	3.08	Buy	$88.75	34.27% Upside
NUVL Nuvalent	3.08	Buy	$118.91	56.42% Upside
SNDX Syndax Pharmaceuticals	3.00	Buy	$38.00	132.84% Upside

Current Analyst Ratings Breakdown

Latest SNDX, NUVL, MRUS, and CRSP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/26/2025	CRSP CRISPR Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/25/2025	MRUS Merus	Industrial Alliance Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$90.00
8/25/2025	MRUS Merus	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$90.00
8/19/2025	NUVL Nuvalent	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$112.00
8/7/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$65.00 ➝ $80.00
8/6/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$42.00 ➝ $56.00
8/6/2025	MRUS Merus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/6/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$97.00 ➝ $96.00
8/6/2025	SNDX Syndax Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
8/5/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
8/5/2025	CRSP CRISPR Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$38.00 ➝ $42.00

(Data available from 8/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRSP CRISPR Therapeutics	$37.31M	129.32	N/A	N/A	$18.81 per share	2.82
MRUS Merus	$36.13M	138.37	N/A	N/A	$11.13 per share	5.94
NUVL Nuvalent	N/A	N/A	N/A	N/A	$13.03 per share	N/A
SNDX Syndax Pharmaceuticals	$23.68M	59.37	N/A	N/A	$1.83 per share	8.92

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRSP CRISPR Therapeutics	-$366.25M	-$5.43	N/A	N/A	N/A	-1,229.43%	-20.05%	-17.09%	11/4/2025 (Estimated)
MRUS Merus	-$215.33M	-$5.50	N/A	N/A	N/A	-685.64%	-50.28%	-42.00%	10/30/2025 (Estimated)
NUVL Nuvalent	-$260.76M	-$4.90	N/A	N/A	N/A	N/A	-32.58%	-30.14%	11/11/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.89	N/A	N/A	N/A	-428.48%	-130.47%	-56.12%	11/4/2025 (Estimated)

Latest SNDX, NUVL, MRUS, and CRSP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	NUVL Nuvalent	-$1.27	-$1.31	-$0.04	-$1.39	N/A	N/A
8/5/2025	Q1 2025	MRUS Merus	-$1.17	-$2.23	-$1.06	-$2.23	$9.77 million	$8.83 million
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.47	-$1.29	+$0.18	-$2.40	$6.44 million	$0.89 million
8/4/2025	Q2 2025	SNDX Syndax Pharmaceuticals	-$1.01	-$0.83	+$0.18	-$0.83	$26.64 million	$37.96 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
NUVL Nuvalent	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRSP CRISPR Therapeutics	N/A	16.61	16.61
MRUS Merus	N/A	8.39	8.39
NUVL Nuvalent	N/A	13.57	13.57
SNDX Syndax Pharmaceuticals	2.06	4.71	4.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRSP CRISPR Therapeutics	69.20%
MRUS Merus	96.14%
NUVL Nuvalent	97.26%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
CRSP CRISPR Therapeutics	4.30%
MRUS Merus	3.70%
NUVL Nuvalent	10.20%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRSP CRISPR Therapeutics	460	90.95 million	87.04 million	Optionable
MRUS Merus	37	75.63 million	72.84 million	Optionable
NUVL Nuvalent	40	72.11 million	64.75 million	Optionable
SNDX Syndax Pharmaceuticals	110	86.14 million	82.61 million	Optionable

SNDX, NUVL, MRUS, and CRSP Headlines

Recent News About These Companies

Syndax Announces Participation in September Investor Conferences

August 26 at 7:00 AM | globenewswire.com

Candriam S.C.A. Has $5.53 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX

August 24, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. $SNDX Shares Bought by Aberdeen Group plc

August 24, 2025 | marketbeat.com

Deutsche Bank AG Has $2.52 Million Position in Syndax Pharmaceuticals, Inc. $SNDX

August 22, 2025 | marketbeat.com

Dennis Podlesak Sells 19,200 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Stock

August 20, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Dennis Podlesak Sells 19,200 Shares

August 20, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Acquired by Algert Global LLC

August 19, 2025 | marketbeat.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Director Sells $298,368.00 in Stock

August 19, 2025 | insidertrades.com

Regulatory Milestone and Analyst Optimism Fuel Momentum for Syndax Pharmaceuticals

August 18, 2025 | insidermonkey.com

BTIG Raises Syndax Pharmaceuticals (SNDX) PT to $56 Following Strong Q2 Revenue from Revuforj, Niktimvo

August 18, 2025 | msn.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 4.4% - Time to Buy?

August 16, 2025 | marketbeat.com

Syndax Pharmaceuticals (SNDX) Is Up 15.8% After Revenue Surges in Q2 2025 Results Has Sentiment Shifted?

August 15, 2025 | finance.yahoo.com

Aigen Investment Management LP Buys Shares of 24,158 Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

August 15, 2025 | marketbeat.com

Does Syndax (SNDX) Have the Potential to Rally 158.36% as Wall Street Analysts Expect?

August 14, 2025 | zacks.com

Syndax Pharmaceuticals: A Tale Of Two Drug Launches

August 13, 2025 | seekingalpha.com

Syndax Pharmaceuticals Sees Unusually Large Options Volume (NASDAQ:SNDX)

August 13, 2025 | marketbeat.com

FDA Priority Review and Revenue Growth Drive Short-Term Upswing for Syndax Pharmaceuticals

August 13, 2025 | insidermonkey.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Recommendation of "Buy" by Brokerages

August 11, 2025 | marketbeat.com

Analysts Just Made A Dazzling Upgrade To Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Forecasts

August 10, 2025 | finance.yahoo.com

Syndax Pharmaceuticals’ Earnings Call Highlights Robust Growth

August 9, 2025 | theglobeandmail.com

Syndax Pharmaceuticals (SNDX) Gets a Buy from Goldman Sachs

August 9, 2025 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNDX, NUVL, MRUS, and CRSP Company Descriptions

CRISPR Therapeutics NASDAQ:CRSP

$53.05 -0.48 (-0.90%)

Closing price 04:00 PM Eastern

Extended Trading

$53.28 +0.23 (+0.44%)

As of 07:55 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Merus NASDAQ:MRUS

$66.10 -1.18 (-1.75%)

Closing price 04:00 PM Eastern

Extended Trading

$64.39 -1.71 (-2.59%)

As of 06:51 PM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Nuvalent NASDAQ:NUVL

$76.02 -0.11 (-0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$76.03 +0.01 (+0.01%)

As of 05:36 PM Eastern

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Syndax Pharmaceuticals NASDAQ:SNDX

$16.32 +0.06 (+0.37%)

Closing price 04:00 PM Eastern

Extended Trading

$16.64 +0.32 (+1.95%)

As of 07:43 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time